Nonobstructive hypertrophic cardiomyopathy (HCM) represents one of the greatest areas of unmet need in HCM management. A key question is identifying the primary driver of symptoms in these patients, as many experience significant functional limitations despite the absence of left ventricular outflow tract obstruction. Understanding the rate and mechanisms of heart failure progression in nonobstructive HCM is also critical, given the substantial morbidity associated with the disease. As a result, there is strong interest in novel therapies that may address underlying disease pathology and improve long-term patient outcomes. 

 

In this interview, Matthew Martinez, MD, FACC and Martin Maron, MD examine treatment for nonobstructive HCM. 

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör American College of Cardiology. Innehållet i podden är skapat av American College of Cardiology och inte av, eller tillsammans med, Poddtoppen.